Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting
Open Access
- 4 September 2015
- journal article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (3) , 499-508
Abstract
The aim of this study was to evaluate the supportive role of molecular and structural biomarkers (CSF protein levels, FDG PET and MRI) in the early differential diagnosis of dementia in a large sample of patients with neurodegenerative dementia, and in determining the risk of disease progression in subjects with mild cognitive impairment (MCI). We evaluated the supportive role of CSF Aβ42, t-Tau, p-Tau levels, conventional brain MRI and visual assessment of FDG PET SPM t-maps in the early diagnosis of dementia and the evaluation of MCI progression. Diagnosis based on molecular biomarkers showed the best fit with the final diagnosis at a long follow-up. FDG PET SPM t-maps had the highest diagnostic accuracy in Alzheimer’s disease and in the differential diagnosis of non-Alzheimer’s disease dementias. The p-tau/Aβ42 ratio was the only CSF biomarker providing a significant classification rate for Alzheimer’s disease. An Alzheimer’s disease-positive metabolic pattern as shown by FDG PET SPM in MCI was the best predictor of conversion to Alzheimer’s disease. In this clinical setting, FDG PET SPM t-maps and the p-tau/Aβ42 ratio improved clinical diagnostic accuracy, supporting the importance of these biomarkers in the emerging diagnostic criteria for Alzheimer’s disease dementia. FDG PET using SPM t-maps had the highest predictive value by identifying hypometabolic patterns in different neurodegenerative dementias and normal brain metabolism in MCI, confirming its additional crucial exclusionary role.Keywords
This publication has 55 references indexed in Scilit:
- Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementiaNeuroImage: Clinical, 2015
- Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical settingNeuroImage: Clinical, 2014
- Characteristics of patients misdiagnosed with Alzheimer’s disease and their medication use: an analysis of the NACC-UDS databaseBMC Geriatrics, 2013
- Combination of 18 F-FDG PET and Cerebrospinal Fluid Biomarkers as a Better Predictor of the Progression to Alzheimer's Disease in Mild Cognitive Impairment PatientsJournal of Alzheimer’s Disease, 2013
- A Comparison of the Diagnostic Sensitivity of MRI, CBF-SPECT, FDG-PET and Cerebrospinal Fluid Biomarkers for Detecting Alzheimer’s Disease in a Memory ClinicDementia and Geriatric Cognitive Disorders, 2010
- Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimer DiseaseAmerican Journal of Neuroradiology, 2010
- Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Chapter 4 Functional neuroimaging of cognition2008
- FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's diseaseBrain, 2007
- Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PETNeuroImage, 2002